Redeye briefly comments on Alligator Bioscience announcing the outcome of its rights issue, with 64.8% subscribed including and excluding pre-emptive rights, and guarantees covering a further 9.1%. As a result, the company will receive SEK91m before issue costs and loan repayments (loan repayments amount to approximately SEK28.5m). The capital raise secures the company’s runway into early Q3 2026e, which could be further extended via TO14 in March 2026.
LÄS MER
